Dialysis-Cohort Imaging Studies of Sclerostin and Calcification Scores

What the evidence says

The sources here link circulating sclerostin to vascular calcification in dialysis and kidney disease cohorts, but the direction depends on the calcification site and the population. All of the evidence is associational, and no source reports a quantified effect size for the sclerostin–calcification link. A 2026 review reports that higher sclerostin in dialysis patients has been associated with less severe aortic valve and aortic wall calcification in several cohorts. The same review reports that, across CKD cohorts, higher sclerostin is frequently associated with greater calcification severity, arterial stiffness and adverse cardiovascular markers. It also reports that in haemodialysis patients, raised sclerostin often correlates with the severity or extent of calcification.

A 2013 haemodialysis study measured two calcification sites directly. Serum sclerostin was 1.78 ± 0.84 ng/mL in patients with aortic valve calcification and 1.35 ± 0.73 ng/mL in those without. The multivariate association with aortic valve calcification extent was P = 0.0170. The same study found no independent association between serum sclerostin and coronary artery calcification, and its authors say they do not know why. The cohort had high calcification burden. Coronary calcification (Agatston score above 100) was present in 65% of the CT group, and any aortic valve calcification in 40%.

Tissue data fit a local role for sclerostin in the valve. In 10 calcified uraemic aortic valves, sclerostin staining sat very close to calcified regions and was absent in non-calcified valves. Sclerostin mRNA was upregulated in calcified valves compared with non-calcified controls. These are descriptive findings from a small sample. They show co-location, not a direction of causation. Sclerostin level itself was higher in haemodialysis patients than in controls without overt CKD (1.53 ± 0.81 versus 0.76 ± 0.31 ng/mL).

One cohort of 44 pre-dialysis ESKD patients adds cardiovascular and mortality outcomes. Sclerostin at or above 218.18 pmol/L went with echocardiographic structural abnormalities, especially pulmonary hypertension (P < 0.01). Sclerostin correlated with pulmonary artery pressure at r = 0.67. A systemic vascular calcification score over 1 point carried a hazard ratio of 11.49 for all-cause mortality (95% CI 2.48–53.14), and pulmonary hypertension carried 5.47 (95% CI 1.30–23.06). In the same cohort, sclerostin did not predict new-onset cardiovascular events (OR 2.69, 95% CI 0.89–8.13, P = 0.08). Eleven of 44 patients died during follow-up. These estimates rest on very few events.

On mechanism, the sources establish none. The review names three possibilities for the positive association: a causal effect, a compensatory response, or a biomarker-only relationship. It does not say which holds. Phosphate is one candidate input. Some dialysis cohorts show a positive correlation between serum phosphate and sclerostin, and others show unchanged or reduced sclerostin depending on dialysis modality, vitamin D supplementation or phosphate concentration.

Where the evidence splits

The review reports an inverse association between sclerostin and aortic valve and wall calcification in dialysis patients. The 2013 haemodialysis study found a positive association with aortic valve calcification. The sources on this page do not explain the split. The review does not say which cohorts produced the inverse finding. It flags the possibility of study population selection and says the relationship with dialysis-specific inverse findings is an "apparent paradox".

Within the 2013 cohort, sclerostin tracked aortic valve calcification but not coronary artery calcification. The authors call the lack of a coronary association unclear. Differences in calcification site are one visible difference, but the sources do not say that site explains the split.

Sclerostin levels in dialysis patients are described both as elevated, often correlating with calcification severity, and as unchanged or even reduced. The review names dialysis modality, vitamin D supplementation and serum phosphate as the factors involved. It does not say how each factor shifts the result. Its own wording is that independent control of these factors is still needed.

Thresholds and dose-response

Two cutoffs appear, both from the small pre-dialysis cohort of 44 patients. Sclerostin at or above 218.18 pmol/L went with structural cardiac abnormalities, especially pulmonary hypertension. A systemic vascular calcification score over 1 point went with a hazard ratio of 11.49 for all-cause mortality. Both come from one small cohort and are not replicated in the sources here. The Agatston score above 100 is the study's definition of coronary calcification in the haemodialysis cohort, not an established point where an effect appears.

Open empirical questions

• Does sclerostin precede calcification, follow it, or only mark it? Every source here is cross-sectional or observational, and none tests direction over time.
• Why do some dialysis cohorts show an inverse sclerostin–calcification association and others a positive one? The sources do not isolate dialysis modality, vitamin D supplementation or phosphate.
• Why does sclerostin track aortic valve calcification but not coronary calcification in the 2013 haemodialysis cohort, and does that pattern replicate elsewhere?
• Do the 218.18 pmol/L and score-over-1 cutoffs hold in larger, independent cohorts, and in patients already on dialysis?